| Malawi | Uganda | Zimbabwe | ||||||
---|---|---|---|---|---|---|---|---|---|
 | Primary | Secondary | Tertiary | Primary | Secondary | Tertiary | Primary | Secondary | |
 | (n = 9) | (n = 3) | (n = 1) | (n = 6) | (n = 16) | (n = 2) | (n = 15) | (n = 6) | |
CD4 testing regularly used prior to initiation | |||||||||
  In all patients | 0 | 1 | 1 | 1 | 4 | 0 | 9 | 2 | |
  Selected patients1 | 4 | 2 | 0 | 4 | 11 | 2 | 4 | 3 | |
  Not used regularly | 5 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | |
CD4 monitoring on ART in adults | |||||||||
  Every 3 months | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | |
  Every 6 months | 0 | 0 | 0 | 5 | 11 | 2 | 10 | 2 | |
  Every 12 months | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | |
  If clinically indicated | 3 | 1 | 0 | 0 | 2 | 0 | 1 | 1 | |
  Not used regularly | 6 | 2 | 1 | 0 | 1 | 0 | 2 | 1 | |
CD4 monitoring on ART in children | |||||||||
  Every 3 months | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | |
  Every 6 months | 0 | 0 | 0 | 4 | 11 | 1 | 9 | 3 | |
  Every 12 months | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | |
  If clinically indicated | 3 | 1 | 0 | 0 | 2 | 0 | 1 | 1 | |
  Not used regularly | 6 | 2 | 1 | 0 | 1 | 0 | 2 | 1 | |
Viral load monitoring on ART | |||||||||
  If clinically indicated | 1 | 0 | 1 | 0 | 1 | 2 | 1 | 0 | |
  Not used regularly | 8 | 3 | 0 | 6 | 15 | 0 | 14 | 6 |